跳至主要内容
临床试验/ACTRN12618000201279
ACTRN12618000201279已完成未知

Effect of positional distribution of fatty acids at the triglyceride backbone of dietary vegetable fats on fat deposition and selected health outcome measures in healthy Australian men and women

CSIRO Health and Biosecurity0 个研究点目标入组 92 人开始时间: 2018年2月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
92

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
20 Years 至 45 Years(—)
性别
All

入选标准

  • 1.Healthy adults
  • 2.BMI 18.5-27.5 kg/m2
  • 3.Understand the study requirements and willing to adhere closely to prescribed food consumption as per the research protocol

排除标准

  • 1.Self-reported history of any of the following chronic diseases - type 2 diabetes, hypertension, coronary heart disease, hyperlipidemia, liver disease, cancer (excluding skin cancer), haemochromatosis
  • 2.Self-reported history of pancreatic insufficiency or other conditions resulting in fat malabsorption - chronic pancreatitis, cystic fibrosis, coeliac disease, Crohns disease, gastric bypass surgery, small bowel resection, abnormal thyroid function
  • 3.On medication/nutraceuticals that may affect liver function, blood lipids, blood pressure or body weight, as assessed by the Principal Investigator or designee
  • 4.Self-reported history of claustrophobia – to enable MRS/MRI assessments to be performed
  • 5.Presence of any ferrous metal in the body - to enable MRS/MRI assessments to be performed.
  • 6.Self-reported pregnant or currently lactating women
  • 7.Females who are post-menopausal, on hormone replacement therapy or on hormone based contraceptives, unless they are stable for at least 3 months prior to study commencement (no changes in type and dose) and have no intention to change during study
  • 8.History of smoking during the 6 months prior to the study
  • 9.Alcohol consumption >21 units per week for men & >14 units per week for women
  • 10.Mean blood pressure >140/90 mmHg assessed at screening visit
  • 11.Hyperlipidemia (fasting TC>6.2 mmol/L or TAG >2.0 mmol/L) assessed at screening visit
  • 12.Abnormal serum liver enzymes (ALT, AST) assessed at screening visit
  • 13.Extended absences due to travel or other commitments
  • 14.Self-reported known allergies to intervention foods
  • 15.On any weight-loss program

研究者

发起方
CSIRO Health and Biosecurity

相似试验